Randomized trial · people
Tesamorelin: visceral fat down 18% over 52 weeks in HIV patients
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, tesamorelin's drop in visceral fat and triglycerides held for a year of use but did not last once it was stopped.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2008
- Journal
- AIDS
What they tested
The team tested whether tesamorelin stays safe and keeps its effects on deep belly fat and blood fats when HIV patients use it for a full year, and what happens when they stop.
How the study was done
A randomized, placebo-controlled trial in HIV patients on antiretroviral therapy (HIV medicines) with fat building up around the middle. 273 got tesamorelin 2 mg and 137 got placebo (a dummy shot) under the skin daily for 26 weeks. Then the tesamorelin group was re-randomized to keep going (154) or switch to placebo (50), and the placebo group switched to tesamorelin (111) for another 26 weeks.

What they found
In people on tesamorelin for the full 52 weeks, visceral adipose tissue (VAT, the deep fat around the organs) stayed 18% lower than at the start (P < 0.001), and triglycerides (a blood fat) stayed 51 mg/dl lower (P < 0.001). Total cholesterol also stayed lower, while HDL cholesterol dropped slightly. Side effects and serious side effects in the second 26 weeks were about as common as in the first, and blood sugar measures did not change in a clinically meaningful way. In people switched from tesamorelin to placebo, the visceral fat came back.
What it doesn’t show
The trial only included HIV patients on antiretroviral therapy with fat buildup around the middle, so it does not show effects in other groups. The extension lasted 26 weeks, and the group switched to placebo was small, at 50 people.
The paper
Falutz et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.